Executive record

Tina S. Nova, Ph.D.

Director at Aurinia Pharmaceuticals Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:tina-s-nova-ph-dVersion: public-0As of: 2026-09-29

Not yet claimed13 published Claims6 sources
  • Director

Key Claims

Biography

Tina S. Nova, Ph.D. has served as Executive Chairman of Exagen since June 2023. She previously served as President of the U.S. CLIA business at Veracyte and as Chief Executive Officer and President of Genoptix, Decipher, and Molecular Stethoscope. She brings extensive leadership and scientific expertise in diagnostics and biopharmaceutical industry with experience in successfully developing, launching, and commercializing medical products.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Dates not publishedExecutive title: Executive Chairman of the Board · Organization not publishedXGN DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

6 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. AUPH DEF 14A director slate

    sec filing · Source published: Apr 21, 2026 · Retrieved: May 15, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Audit, Nominating/Governance · Claim reviewed: May 15, 2026

  2. Open source

    sec proxy · Source published: Apr 21, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Aurinia Pharmaceuticals Inc. · Claim reviewed: May 16, 2026

  3. XGN DEF 14A director slate

    sec filing · Source published: Apr 30, 2025 · Retrieved: May 16, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Chair · Claim reviewed: May 16, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Exagen Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Executive Chairman of the Board · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  4. Open source

    sec proxy · Source published: Apr 30, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at EXAGEN INC. · Claim reviewed: May 16, 2026

  5. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Aurinia Pharmaceuticals Inc. · Claim reviewed: May 16, 2026

  6. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of EXAGEN INC. · Claim reviewed: May 16, 2026